Sectors & Industries HealthcareDiagnostics & Research
Best Diagnostic & Research Stocks to Buy Now (2026)
Top diagnostic & research stocks in 2026 ranked by overall Zen Rating. "A" Rated stocks have returned an average of +32.52% per year, and are the best diagnostic & research stocks to buy now. Learn More.

Industry: Diagnostics & Research

Overview Zen Rating Price Value Growth Financials Momentum Sentiment

Diagnostics & Research is Zen Rated B and is the 40th ranked industry out of 145 stock market industries

Ticker	Company	Market Cap	Shares	Institutional %	Insider %	Net Insider (L12M)	Net Insider (L3M)
ILMN	ILLUMINA INC	$18.49B	152,900,000	93.45%	6.55%	Net Buying	Net Buying
SHC	SOTERA HEALTH CO	$4.37B	284,392,079	86.76%	13.24%	Net Selling	Net Selling
BLLN	BILLIONTOONE INC	$3.73B	45,965,812	18.60%	25.95%	Net Buying
TMO	THERMO FISHER SCIENTIFIC INC	$184.30B	371,484,244	99.09%	0.91%	Net Buying	Net Selling
MTD	METTLER TOLEDO INTERNATIONAL INC	$26.93B	20,325,250	95.44%	4.56%	Net Buying	Net Buying
IDXX	IDEXX LABORATORIES INC	$44.83B	79,624,034	98.26%	1.74%	Net Buying	Net Selling
A	AGILENT TECHNOLOGIES INC	$32.52B	282,602,317	90.80%	1.28%	Net Buying	Net Buying
PRPO	PRECIPIO INC	$48.61M	1,783,682	0.59%	99.41%	Net Buying	Net Buying
BNR	BURNING ROCK BIOTECH LTD	$166.01M	104,768,957	1.63%	18.05%	Net Buying	Net Buying
MEDP	MEDPACE HOLDINGS INC	$14.01B	28,381,283	26.66%	73.34%	Net Selling	Net Buying
DHR	DANAHER CORP	$134.08B	707,139,356	76.09%	23.91%	Net Selling	Net Selling
CAI	CARIS LIFE SCIENCES INC	$5.10B	282,579,919	40.00%	60.00%	Net Selling	Net Buying
RVTY	REVVITY INC	$10.04B	111,799,374	97.25%	2.75%	Net Selling	Net Selling
NEOG	NEOGEN CORP	$2.05B	217,673,041	97.85%	2.15%	Net Buying	Net Buying
IQV	IQVIA HOLDINGS INC	$28.40B	169,700,000	53.65%	46.35%	Net Selling	Net Selling
LH	LABCORP HOLDINGS INC	$21.50B	82,400,000	96.94%	1.62%	Net Selling	Net Selling
BDSX	BIODESIX INC	$129.44M	9,858,358	3.92%	96.08%	Net Buying	Net Buying
CRL	CHARLES RIVER LABORATORIES INTERNATIONAL INC	$8.65B	49,227,800	96.61%	3.39%	Net Buying	Net Selling
WAT	WATERS CORP	$31.39B	98,101,871	58.81%	4.95%	Net Selling	Net Selling
MYGN	MYRIAD GENETICS INC	$406.76M	93,508,165	89.76%	10.24%	Net Selling	Net Selling
CDNA	CAREDX INC	$822.02M	51,216,344	77.03%	22.97%	Net Selling	Net Selling
NTRA	NATERA INC	$27.36B	141,731,250	80.36%	19.64%	Net Selling	Net Selling
DGX	QUEST DIAGNOSTICS INC	$21.04B	109,866,320	96.61%	1.83%	Net Selling	Net Buying
NEO	NEOGENOMICS INC	$998.26M	129,812,211	72.92%	27.08%	Net Buying	Net Selling
QGEN	QIAGEN NV	$8.87B	216,920,735	69.19%	0.00%
CSTL	CASTLE BIOSCIENCES INC	$687.68M	29,731,198	86.03%	13.97%	Net Selling	Net Selling
ICLR	ICON PLC	$8.16B	76,359,932	99.47%	0.53%
LAB	STANDARD BIOTOOLS INC	$345.21M	390,071,506	49.08%	50.92%	Net Buying	Net Selling
RDNT	RADNET INC	$4.30B	77,612,125	71.06%	28.94%	Net Selling	Net Selling
TWST	TWIST BIOSCIENCE CORP	$2.94B	61,311,704	88.68%	11.32%	Net Selling	Net Selling
PSNL	PERSONALIS INC	$629.88M	104,631,832	68.86%	31.14%	Net Buying	Net Buying
BIAF	BIOAFFINITY TECHNOLOGIES INC	$15.07M	4,498,675	1.60%	98.40%
PRE	PRENETICS GLOBAL LTD	$284.29M	16,034,309	10.85%	8.69%
MDXH	MDXHEALTH SA	$10.48M	51,364,520	43.94%	56.06%
GH	GUARDANT HEALTH INC	$10.31B	131,170,441	68.88%	31.12%	Net Selling	Net Selling
XGN	EXAGEN INC	$72.88M	24,053,058	44.97%	47.08%	Net Selling	Net Buying
OPK	OPKO HEALTH INC	$890.53M	767,701,280	20.62%	79.38%	Net Buying	Net Buying
XWEL	XWELL INC	$9.43M	7,926,766	1.49%	98.51%
ACRS	ACLARIS THERAPEUTICS INC	$437.71M	108,345,239	56.41%	43.59%	Net Selling	Net Selling
FLGT	FULGENT GENETICS INC	$450.66M	31,230,632	57.16%	41.96%	Net Selling	Net Selling
STIM	NEURONETICS INC	$92.46M	68,485,922	55.62%	44.38%	Net Selling	Net Buying
GRAL	GRAIL INC	$1.78B	38,982,223	76.73%	20.80%	Net Selling	Net Selling
IMDX	INSIGHT MOLECULAR DIAGNOSTICS INC	$101.97M	32,167,978	16.79%	83.21%	Net Buying	Net Buying
MBAI	CHECK-CAP LTD	$255.30M	151,962,777	0.02%	0.00%
ISPC	ISPECIMEN INC	$3.80M	29,662,250	0.43%	21.77%
DRIO	DARIOHEALTH CORP	$52.93M	7,300,406	5.02%	94.98%	Net Buying
BNBX	BNB PLUS CORP	$3.16M	5,447,469	2.37%	97.63%
ADVB	ADVANCED BIOMED INC	$7.14M	1,082,000	4.08%	0.00%
TRIB	TRINITY BIOTECH PLC	$13.19M	369,329,458	0.23%	0.13%
NDRA	ENDRA LIFE SCIENCES INC	$6.13M	1,240,751	5.33%	94.67%	Net Buying
SERA	SERA PROGNOSTICS INC	$77.11M	39,143,848	45.32%	25.38%	Net Selling	Net Selling
FONR	FONAR CORP	$122.46M	6,555,521	39.45%	3.60%
NOTV	INOTIV INC	$7.88M	34,394,971	22.01%	39.39%	Net Selling	Net Selling
VNRX	VOLITIONRX LTD	$26.31M	158,481,243	10.19%	25.62%	Net Buying	Net Selling
QUCY	MAINZ BIOMED NV	$5.54M	12,515,336	9.20%	14.57%	Net Buying

Diagnostic & Research Stocks FAQ

What are the best diagnostic & research stocks to buy right now in Apr 2026?

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best diagnostic & research stocks to buy right now are:

1. Illumina (NASDAQ:ILMN)

Illumina (NASDAQ:ILMN) is the #1 top diagnostic & research stock out of 55 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Illumina (NASDAQ:ILMN) is: Value: B, Growth: C, Momentum: C, Sentiment: B, Safety: B, Financials: A, and AI: B.

Illumina (NASDAQ:ILMN) has a Due Diligence Score of 37, which is 9 points higher than the diagnostic & research industry average of 28.

ILMN passed 12 out of 33 due diligence checks and has average fundamentals. Illumina has seen its stock return 69.7% over the past year, overperforming other diagnostic & research stocks by 43 percentage points.

Illumina has an average 1 year price target of $138.60, an upside of 14.61% from Illumina's current stock price of $120.93.

Illumina stock has a consensus Buy recommendation according to Wall Street analysts. Of the 10 analysts covering Illumina, 30% have issued a Strong Buy rating, 10% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 10% have issued a Strong Sell.

2. Sotera Health Co (NASDAQ:SHC)

Sotera Health Co (NASDAQ:SHC) is the #2 top diagnostic & research stock out of 55 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Sotera Health Co (NASDAQ:SHC) is: Value: C, Growth: C, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: C.

Sotera Health Co (NASDAQ:SHC) has a Due Diligence Score of 33, which is 5 points higher than the diagnostic & research industry average of 28.

SHC passed 11 out of 33 due diligence checks and has average fundamentals. Sotera Health Co has seen its stock return 44.91% over the past year, overperforming other diagnostic & research stocks by 18 percentage points.

Sotera Health Co has an average 1 year price target of $21.40, an upside of 39.32% from Sotera Health Co's current stock price of $15.36.

Sotera Health Co stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 5 analysts covering Sotera Health Co, 60% have issued a Strong Buy rating, 20% have issued a Buy, 20% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Billiontoone (NASDAQ:BLLN)

Billiontoone (NASDAQ:BLLN) is the #3 top diagnostic & research stock out of 55 with a Zen Rating of B. Stocks with a rating of B have had an average return of +19.88% per year. Learn more.

The Component Grade breakdown for Billiontoone (NASDAQ:BLLN) is: Value: C, Growth: B, Momentum: C, Sentiment: A, Safety: C, Financials: C, and AI: C.

Billiontoone (NASDAQ:BLLN) has a Due Diligence Score of 56, which is 28 points higher than the diagnostic & research industry average of 28.

BLLN passed 18 out of 33 due diligence checks and has strong fundamentals.

Billiontoone has an average 1 year price target of $126.71, an upside of 56.19% from Billiontoone's current stock price of $81.13.

Billiontoone stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 7 analysts covering Billiontoone, 71.43% have issued a Strong Buy rating, 0% have issued a Buy, 28.57% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

What are the diagnostic & research stocks with highest dividends?

Out of 6 diagnostic & research stocks that have issued dividends in the past year, the 3 diagnostic & research stocks with the highest dividend yields are:

1. Quest Diagnostics (NYSE:DGX)

Quest Diagnostics (NYSE:DGX) has an annual dividend yield of 1.7%, which is 1 percentage points higher than the diagnostic & research industry average of 0.84%. Quest Diagnostics's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Quest Diagnostics's dividend has shown consistent growth over the last 10 years.

Quest Diagnostics's dividend payout ratio of 36.1% indicates that its dividend yield is sustainable for the long-term.

2. Labcorp Holdings (NYSE:LH)

Labcorp Holdings (NYSE:LH) has an annual dividend yield of 1.1%, which is the same as the diagnostic & research industry average of 0.84%. Labcorp Holdings's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Labcorp Holdings's dividend has not shown consistent growth over the last 10 years.

Labcorp Holdings's dividend payout ratio of 27.3% indicates that its dividend yield is sustainable for the long-term.

3. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) has an annual dividend yield of 0.87%, which is the same as the diagnostic & research industry average of 0.84%. Agilent Technologies's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Agilent Technologies's dividend has shown consistent growth over the last 10 years.

Agilent Technologies's dividend payout ratio of 22% indicates that its dividend yield is sustainable for the long-term.

Why are diagnostic & research stocks down?

Diagnostic & research stocks were down -1.77% in the last day, and down -0.17% over the last week. Ispecimen was the among the top losers in the diagnostics & research industry, dropping -1.54% yesterday.

iSpecimen shares are trading higher after the company announced it reduced its domestic shipments transit times.

What are the most undervalued diagnostic & research stocks?

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued diagnostic & research stocks right now are:

1. Icon (NASDAQ:ICLR)

Icon (NASDAQ:ICLR) is the most undervalued diagnostic & research stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Icon has a valuation score of 100, which is 85 points higher than the diagnostic & research industry average of 15. It passed 7 out of 7 valuation due diligence checks.

Icon's stock has dropped -25.12% in the past year. It has underperformed other stocks in the diagnostic & research industry by -52 percentage points.

2. Qiagen Nv (NYSE:QGEN)

Qiagen Nv (NYSE:QGEN) is the second most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Qiagen Nv has a valuation score of 43, which is 28 points higher than the diagnostic & research industry average of 15. It passed 3 out of 7 valuation due diligence checks.

Qiagen Nv's stock has gained 2.1% in the past year. It has underperformed other stocks in the diagnostic & research industry by -25 percentage points.

3. Agilent Technologies (NYSE:A)

Agilent Technologies (NYSE:A) is the third most undervalued diagnostic & research stock based on its Valuation Rating of B. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Agilent Technologies has a valuation score of 14, which is -1 points higher than the diagnostic & research industry average of 15. It passed 1 out of 7 valuation due diligence checks. Although this number is below the industry average, our proven quant model rates A a Valuation Rating of "B".

Agilent Technologies's stock has gained 15.12% in the past year. It has underperformed other stocks in the diagnostic & research industry by -12 percentage points.

Are diagnostic & research stocks a good buy now?

51.16% of diagnostic & research stocks rated by analysts are a strong buy right now. On average, analysts expect diagnostic & research stocks to rise by 26.66% over the next year.

2.33% of diagnostic & research stocks have a Zen Rating of A (Strong Buy), 27.91% of diagnostic & research stocks are rated B (Buy), 53.49% are rated C (Hold), 16.28% are rated D (Sell), and 0% are rated F (Strong Sell).

What is the average p/e ratio of the diagnostics & research industry?

The average P/E ratio of the diagnostics & research industry is 21.66x.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.

Diagnostic & Research Stocks FAQ

1. Illumina (NASDAQ:ILMN)

2. Sotera Health Co (NASDAQ:SHC)

3. Billiontoone (NASDAQ:BLLN)

1. Quest Diagnostics (NYSE:DGX)

2. Labcorp Holdings (NYSE:LH)

3. Agilent Technologies (NYSE:A)

1. Icon (NASDAQ:ICLR)

2. Qiagen Nv (NYSE:QGEN)

3. Agilent Technologies (NYSE:A)

Company

Stock Tools

Stock Ideas